What question did this study set out to answer?

The aim is to determine the effectiveness of short-term blinatumomab in achieving measurable residual disease negativity in pediatric B-ALL.

May 9, 2026Annals of HematologyOpen Access

Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance

View Full Paper

Ask AI

Bookmark

The aim is to determine the effectiveness of short-term blinatumomab in achieving measurable residual disease negativity in pediatric B-ALL.
30 patients received 14-day blinatumomab infusion while 30 continued standard chemotherapy.
Primary endpoint focused on MRD complete remission rate after blinatumomab therapy.
Secondary endpoints included safety and long-term outcomes.
100% of the blinatumomab group achieved MRD negativity within one week.
Median time to MRD negativity was 39 days for blinatumomab versus 42.5 days for standard chemotherapy (p = 0.0243).
3-year overall survival was 100% in the blinatumomab group compared to 85.9% in the control group (p = 0.0360).

No takes yet. Share an insight, caveat, or question.

Randomized trial shows high MRD clearance in pediatric B-ALL patients with blinatumomab, indicating a promising treatment option.

Xue et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark